OSE Immunotherapeutics
Clinical-stage biotech developing immune therapies for oncology and inflammation.
OSE | PA
Overview
Corporate Details
- ISIN(s):
- FR0012127173 (+2 more)
- LEI:
- 969500HIUWVGY6NZSM05
- Country:
- France
- Address:
- 22 BOULEVARD BENONI GOULLIN, 44200 NANTES
- Sector:
- Manufacturing
Description
OSE Immunotherapeutics is a clinical-stage biotechnology company focused on developing and partnering first-in-class therapies that control the immune system. The company's pipeline is concentrated in two key areas: immuno-oncology (IO) and immuno-inflammation (I&I). In immuno-oncology, its research aims to help the immune system recognize and target tumors. In immuno-inflammation, it develops treatments for autoimmune diseases and chronic inflammation by regulating immune responses. OSE Immunotherapeutics utilizes proprietary drug discovery platforms to generate novel product candidates, including monoclonal antibodies and RNA therapeutics, and collaborates with pharmaceutical partners to advance its assets through clinical development.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-12-09 07:30 |
OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities…
|
English | 238.4 KB | ||
| 2025-12-09 07:30 |
OSE Immunotherapeutics dévoile son plan stratégique 2026 - 2028 axé sur quatre…
|
French | 294.7 KB | ||
| 2025-12-08 07:30 |
OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on…
|
English | 227.8 KB | ||
| 2025-12-08 07:30 |
OSE Immunotherapeutics annonce un amendement stratégique au partenariat avec Ab…
|
French | 229.0 KB | ||
| 2025-11-17 18:00 |
OSE Immunotherapeutics Announces Positive Recommendation from Independent Data …
|
English | 228.0 KB | ||
| 2025-11-17 18:00 |
OSE Immunotherapeutics annonce que le Comité indépendant d’experts scientifique…
|
French | 204.8 KB | ||
| 2025-11-07 18:00 |
Présentation poster sur OSE-Cytomask®, une technologie innovante de « Cis-Démas…
|
French | 219.9 KB | ||
| 2025-11-07 18:00 |
OSE Immunotherapeutics Presents a Poster on OSE-Cytomask®, a Novel “Cis-Demaski…
|
English | 240.7 KB | ||
| 2025-11-03 18:00 |
Informations relatives au nombre total de droits de vote et d’actions composant…
|
French | 196.0 KB | ||
| 2025-10-30 18:00 |
Informations relatives au nombre total de droits de vote et d’actions composant…
|
French | 585.6 KB | ||
| 2025-10-16 19:58 |
RAPPORT FINANCIER SEMESTRIEL 2025
|
French | 1.2 MB | ||
| 2025-10-15 19:00 |
OSE Immunotherapeutics Reports First Half 2025 Financial Results
|
English | 215.4 KB | ||
| 2025-10-15 19:00 |
OSE Immunotherapeutics publie ses résultats financiers du 1er semestre 2025
|
French | 215.6 KB | ||
| 2025-10-09 15:57 |
Franchissement de seuils
|
French | 120.1 KB | ||
| 2025-10-03 08:00 |
Appointment of Marc Le Bozec as Interim CEO
|
English | 212.1 KB |
Automate Your Workflow. Get a real-time feed of all OSE Immunotherapeutics filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for OSE Immunotherapeutics
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for OSE Immunotherapeutics via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-06-19 | N/A | Other | Other | 10,000 | 35,700.00 EUR |
| 2024-06-17 | N/A | Other | Other | 10,000 | 35,800.00 EUR |
| 2024-06-17 | N/A | Other | Other | 10,000 | 35,700.00 EUR |
| 2024-06-13 | N/A | Other | Sell | 6,369 | 45,879.09 EUR |
| 2024-06-03 | N/A | Other | Sell | 40,000 | 314,512.00 EUR |
Peer Companies
